ABEO

Abeona Therapeutics Inc.

Fundamental data last updated:July 27, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/13/2026

Business Summary

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

 


Analyze ABEO on TradingView

VALUATION

P/E

4.99

Market Cap ($M USD)

$332.00M

Forward P/E

2.96

PEG

0.04

PRICE TO SALES

22.83

PRICE TO BOOK

2.28

EV / EBITDA

4.41

5-Year Average P/E

Free Cash Flow Yield

-25.67%

DCF Value

$0.80

Graham Number

$8.20

Price to FCF

-3.89

EV to FCF

-3.45

Earnings Yield

20.05%

FCF Yield

-25.67%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.17

Next Year EPS Growth Estimate

$1.97

Next Year Revenue Growth Estimate

$34.99B

Return on Equity (ROE)

41.40%

FREE CASH FLOW

Operating Margin

-637.92%

Debt-to-Equity

0.16

Piotroski F-Score

6

Altman Z-Score

0.32

Return on Invested Capital (ROIC)

-55.39%

Current Ratio

5.89

Quick Ratio

5.70

Net Debt to EBITDA

-0.57

Interest Coverage

-25.97

Gross Profit margin

51.93%

FCF PER SHARE

$-1.51

REVENUE PER SHARE

$0.26

Analyze ABEO on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing Abeona Therapeutics Inc., with its snapshot price significantly below both its DCF Value and Graham Number. The Forward P/E of 2.87 and an Earnings Yield of 22.78% suggest a compelling valuation, yet the Altman Z-score of -1.74 raises red flags about financial distress. Despite a robust Return on Equity of 53.18%, the negative EV to EBITDA and operating margin indicate severe profitability challenges. This juxtaposition of high earnings potential and financial instability paints a complex picture for investors.

AI Exposure / Tech Reliance

In the rapidly evolving biotechnology sector, Abeona Therapeutics is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The company's focus on innovative therapies aligns with technological shifts, potentially enhancing its competitive edge. However, the industry's inherent volatility demands agile adaptation to maintain resilience.

The Bull Case

For value and GARP investors, Abeona Therapeutics presents an intriguing opportunity. The Piotroski F-Score of 6 indicates moderate financial health, while the low Debt/Equity ratio of 0.16 suggests prudent capital management. Despite a negative FCF Yield, the company's strong ROIC of 53.18% highlights its ability to generate returns on invested capital, hinting at potential pricing power and operational efficiency.

The Bear Case

Abeona Therapeutics faces significant structural risks, with a staggering Price/Sales ratio of 57.83 and a Price/Book of 1.96, indicating overvaluation concerns. The negative EV to EBITDA and operating margin of -1536.91% underscore severe profitability issues. Additionally, the Altman Z-score suggests potential financial distress, raising alarms about the company's long-term viability. These metrics highlight the precarious nature of its current financial standing.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$17.00

Institutional Ownership %

1-Year Beta

1.34

Insider Buying % (6 Mo)

Distance to 52-Week High

29.44%

Distance to 52-Week Low

31.33%

EARNINGS SURPRISE %

9.09%

50-DAY SMA

$5.21

200-DAY SMA

$5.34

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.